Process-improved famotidine preparation method

By introducing decolorization, crystallization, alcohol washing and drying steps in the synthesis of famotidine, the purity and yield of famotidine are improved, and the synthesis method of famotidine in the prior art is solved in mass production of famotidine in the prior art The problem of insufficient purity and yield in the process has achieved efficient preparation of famotidine.

CN118955427APending Publication Date: 2024-11-15HUNAN SAILONG PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411040751.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The yield and purity of the existing methods of synthesis of famotidine raw materials are insufficient in large-scale production, which makes it difficult to reduce production costs.

Method used

A process improvement method is adopted, including the purification steps of the crude product of famotidine: decolorization, crystallization, alcohol washing and drying steps, decolorization by dissolving in N,N-dimethylformamide and adding activated carbon, followed by purification Crystallization was performed in water, then beaten in methanol and dried under reduced pressure, which increased the purity and yield of famotidine.

Benefits of technology

The high purity (over 99%) and high yield (80-90%) of famotidine are achieved, which significantly improves the purity and production efficiency of the product and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955427A_ABST
    Figure CN118955427A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of raw material medicine preparation, in particular to a process-improved preparation method of famotidine, which comprises a refining step of a famotidine crude product, a decoloration step, a crystallization step, an alcohol washing step and a drying step in sequence, and the prepared product is crystal powder with pure white appearance. In the preparation process, a high-purity stable intermediate I (2-guanidin-4-chloromethylthiazole hydrochloride) and an intermediate II ((S)-[(2-guanidin-4-thiazolyl) methyl] isothiourea dihydrochloride) can be obtained, the content of famotidine in the final product can reach 99% or above, the impurity content can be controlled to be 0.1% or below, and compared with a preparation method in the prior art, the preparation method has the advantages that the yield is high, and the cost is low. The purity and the yield are obviously improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of raw material medicines, and in particular relates to a method for preparing famotidine with improved process. Background Art

[0002] Famotidine (I), chemical name is 3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N 2 -Sulfonyl propionamidine is a new generation of highly selective histamine H2 receptor antagonists with strong and lasting gastric acid secretion inhibition, mainly used to treat gastric and duodenal ulcers. The yield and purity of the existing famotidine raw material synthesis method need to be improved, and the existing technology is not conducive to reducing production costs in mass production. Summary of the invention

[0003] In view of the above technical problems, the present invention provides a method for preparing famotidine with improved process, comprising a refining step of a crude famotidine product, wherein the refining step of the crude famotidine product specifically comprises:

[0004] S1 decolorization step: dissolve the crude famotidine in N,N-dimethylformamide, add activated carbon, control the temperature to 10-30°C, stir to decolorize for 1 hour, and then filter;

[0005] S2 Crystallization step: Add purified water to the filtrate obtained in the decolorization step, control the temperature at 10-30°C, stir and crystallize for 1-3 hours, and then filter;

[0006] S3 alcohol washing step: dissolving the filter cake obtained in the crystallization step in methanol, stirring and beating at a temperature of 10-30°C for 1 hour, and then filtering;

[0007] In step S4 of drying, the filter cake obtained in the step of washing with alcohol is dried under reduced pressure to obtain a refined famotidine product.

[0008] The product prepared by the invention is a crystalline powder with a pure white appearance. During the preparation process, a high-purity stable intermediate I (2-guanidino-4-chloromethylthiazole hydrochloride) and an intermediate II ((S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride) can be obtained. The famotidine content in the final product can reach more than 99%, and the impurity content can be controlled to be less than 0.1%. Compared with the preparation method in the prior art, the purity and yield are significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 : Flow chart of Example 1;

[0010] Figure 2 : Flow chart of Example 1;

[0011] Figure 3: Flow chart of Example 2;

[0012] Figure 4 : Flow chart of embodiment 3;

[0013] Figure 5 : Flowchart of Example 4. DETAILED DESCRIPTION

[0014] The following examples further illustrate the content of the present invention, but should not be construed as limiting the present invention. Without departing from the spirit and substance of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention all fall within the scope of the present invention.

[0015] There are two synthetic routes of famotidine disclosed in existing literature (Document 1: Dai Xiangrong et al. Synthesis of famotidine [J]. Pharmaceutical Industry, 1987, 18(6); Document 2: Zhou Yuan, Du Fangyan. Improvement of the synthetic process of famotidine [J]. Hubei Chemical Industry, 2000(5)). The main difference between the two synthetic routes disclosed is that the connection method of the side chain (3-chloropropylimidate methyl ester, N-sulfamido-3-chloropropylamidine hydrochloride) is inconsistent. Route 1 uses a two-step reaction to connect the side chain, and Route 2 uses a one-step reaction to connect the side chain.

[0016] Route 1: This route uses guanylthiourea (SM1) and 1,3-dichloroacetone (SM2) as starting materials. SM1 and SM2 are condensed to obtain intermediate I, and intermediate I is reacted with thiourea to obtain intermediate II; intermediate II is condensed with 3-chloropropylimidate to obtain intermediate III; intermediate III is then reacted with sulfonamide to obtain a crude product, which is then recrystallized from purified water to obtain the finished famotidine. The reaction formula is as follows:

[0017]

[0018] Route 2: This route uses guanylthiourea (SM1) and 1,3-dichloroacetone (SM2) as starting materials. SM1 and SM2 are condensed to obtain intermediate I, and intermediate I is reacted with thiourea to obtain intermediate II. Intermediate II is condensed with SM3 (N-sulfamido-3-chloropropionamidine hydrochloride) to obtain a crude product, which is then recrystallized from purified water to obtain the finished famotidine. The reaction formula is as follows:

[0019]

[0020] Compared with Route 1, Route 2 has the following advantages:

[0021] ① Route 1 uses a two-step reaction to connect the side chain, and the total yield is low. Route 2 uses a one-step reaction to connect the side chain, which shortens the reaction steps and improves the total yield;

[0022] ② SM3 in Route 2 is a commercially available chemical that has been industrially produced in China, can exist stably, and is cheap;

[0023] ③ Each step can obtain high-purity and stable intermediates through simple operations such as crystallization;

[0024] ④ Route 2 has short reaction steps and fewer production operation procedures, which is conducive to industrial production.

[0025] Based on Route 2, the following examples of the present invention provide a method for preparing famotidine with improved process.

[0026] Example 1

[0027] The synthesis of famotidine uses guanylthiourea (SM1) and 1,3-dichloroacetone (SM2) as starting materials, and the finished product is obtained through the steps of cyclization, substitution, condensation, and purification as in route 2. The purification step specifically includes: Figure 1 In:

[0028] S1 decolorization step: dissolve the crude famotidine in N,N-dimethylformamide (DMF), add activated carbon, control the temperature to 10-30°C, stir to decolorize for 1 hour, and then filter;

[0029] S2 Crystallization step: Add purified water to the filtrate obtained in the decolorization step, control the temperature at 10-30°C, stir and crystallize for 1-3 hours, and then filter;

[0030] S3 alcohol washing step: dissolving the filter cake obtained in the crystallization step in methanol, stirring and beating at a temperature of 10-30°C for 1 hour, and then filtering;

[0031] In step S4 of drying, the filter cake obtained in the step of washing with alcohol is dried under reduced pressure to obtain a refined famotidine product.

[0032] The purification steps of some embodiments are as follows Figure 2 ,include:

[0033] Add 4.2 kg of crude product and 13 L of DMF (N, N-dimethylformamide) to a 50 L double-layer glass reactor, stir to dissolve, add 210 g of activated carbon, control the temperature to 10-30 ° C and stir to decolorize for 1 hour. After decolorization is completed, filter, slowly add 38 L of purified water to the filtrate, control the temperature to 10-30 ° C and stir to crystallize for 2-3 hours, filter, and collect the filter cake.

[0034] Add the filter cake and 42 L of methanol into a 100 L double-layer glass reactor, stir and slurry at 10-30 ° C for 1 hour, filter, collect the filter cake, and dry under reduced pressure at 70-80 ° C for not less than 6 hours to obtain the famotidine product.

[0035] Table 1. List of materials used for crude product refining

[0036]

[0037] Yield: 80-90%.

[0038] Example 2

[0039] Based on Example 1, the condensation step of this example is specifically carried out through the synthesis step of the crude famotidine product by subjecting (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride and N-sulfuric acid amino-chloropropionamidine hydrochloride to a substitution reaction in 95% ethanol and 1N sodium hydroxide solution to synthesize the crude famotidine product.

[0040] The synthetic steps of the famotidine crude product of more specific embodiment are as follows Figure 3 ,include:

[0041] Add 4.7 kg of intermediate II, 3.8 kg of N-sulfamido-3-chloropropionamidine hydrochloride (SM3) and 47 L of 95% ethanol to a 150 L double-layer glass reactor, stir evenly, control the temperature to 0-10 ° C, slowly add 85.8 L of 1N sodium hydroxide solution, and after the addition, control the temperature to 10-30 ° C and stir to react for 4-5 hours. After 4 hours, start TLC to monitor the reaction progress.

[0042] After the reaction is completed, hydrochloric acid is added to adjust the pH of the system to 10-11, the temperature is lowered to 0-10°C and stirred for crystallization for 2-3 hours, filtered, the filter cake is washed with an appropriate amount of 95% ethanol, and dried under reduced pressure at 70-80°C for not less than 6 hours to obtain crude famotidine.

[0043] Table 2. List of materials used in the synthesis of crude famotidine

[0044]

[0045] ① Yield range: 80-90%

[0046] ②TLC monitoring method:

[0047] Developing solvent: ethyl acetate: methanol = 10:1;

[0048] Detection method: Check under UV254nm;

[0049] End point indication: no UV spot of intermediate II on the TLC plate.

[0050] ③Storage: Keep away from light and keep in sealed container.

[0051] Example 3

[0052] On the basis of Example 1-2, this example also includes the step of synthesizing (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride (Intermediate II). The step of synthesizing Intermediate II specifically includes: mixing 2-guanidino-4-chloromethylthiazole hydrochloride (Intermediate I), thiourea and 95% ethanol, heating to 80±5°C and reflux, stirring and reacting for 4-5h, after the reaction is completed, cooling to 10-30°C and stirring and crystallizing for 1-2h, filtering, washing the filter cake with 95% ethanol and drying under reduced pressure at 70-80°C for not less than 4h, to obtain (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride (Intermediate II).

[0053] The steps of synthesizing intermediate II in a more specific embodiment are as follows Figure 4 , including the following steps:

[0054] Add 4.3 kg of intermediate I, 1.6 kg of thiourea and 22 L of 95% ethanol into a 50 L double-layer glass reactor. After the addition is complete, raise the temperature to reflux (about 80° C.) and stir the reaction for 4-5 h. After 4 h, start TLC to monitor the reaction progress.

[0055] After the reaction is completed, the temperature is lowered to 10-30°C, stirred and crystallized for 1-2 hours, filtered, the filter cake is washed with an appropriate amount of 95% ethanol, the filter cake is collected, and dried under reduced pressure at 70-80°C for not less than 6 hours to obtain intermediate 2.

[0056] Table 3. List of materials used in the synthesis of (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride

[0057]

[0058]

[0059] ① Yield range: 80-90%;

[0060] ②TLC monitoring method:

[0061] Developing solvent: dichloromethane: methanol = 10:1;

[0062] Detection method: Check under UV254nm;

[0063] End point indication: no UV spot of intermediate I on the TLC plate.

[0064] ③Storage: Store at room temperature, sealed.

[0065] Obtain high-purity stable intermediate I (2-guanidino-4-chloromethylthiazole hydrochloride) and intermediate II ((S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride).

[0066] Example 4

[0067] On the basis of Example 1-3, this example also includes the steps of synthesizing 2-guanidino-4-chloromethylthiazole hydrochloride (intermediate I), specifically including:

[0068] (1) After mixing guanylthiourea and 1,3-dichloroacetone in a molar ratio of 1:1.2 in acetone, the mixture was heated slowly to 50°C-55°C, refluxed, and stirred for 3-4 hours to obtain a crude solution of 2-guanidino-4-chloromethylthiazole hydrochloride.

[0069] (2) The crude solution of 2-guanidino-4-chloromethylthiazole hydrochloride was cooled to 10-30°C and stirred for crystallization for 1-2 hours, filtered, and the filter cake was collected. The filter cake and 12L of anhydrous ethanol were added, stirred and slurried at 0-20°C for 1 hour, filtered, and the filter cake was collected. It was dried under reduced pressure at 80-90°C for not less than 4 hours to obtain 2-guanidino-4-chloromethylthiazole hydrochloride (intermediate I).

[0070] More specifically, the steps of synthesizing intermediate I in the embodiment are as follows Figure 5 , including the following steps:

[0071] Add 4.0 kg of guanylthiourea (SM1), 5.2 kg of 1,3-dichloroacetone (SM2) and 24 L of acetone to a 50 L double-layer glass reactor, stir evenly, slowly heat to 50 ° C - reflux (about 55 ° C), stir the reaction for 3-4 hours, and start TLC to monitor the reaction progress after 3 hours.

[0072] After the reaction is completed, cool to 10-30°C, stir and crystallize for 1-2h, filter and collect the filter cake.

[0073] Add the above filter cake and 12 L of anhydrous ethanol into a 50 L double-layer glass reactor, stir and slurry at 0-20 ° C for 1 h, filter, collect the filter cake, and dry under reduced pressure at 80-90 ° C for not less than 6 h to obtain intermediate I.

[0074] Table 4. List of materials used in the synthesis of 2-guanidino-4-chloromethylthiazole hydrochloride (intermediate Ⅰ)

[0075]

[0076] ① Yield range: 55-65%;

[0077] ②TLC monitoring method:

[0078] Developing solvent: dichloromethane: methanol = 10:1;

[0079] Detection method: Check under UV254nm;

[0080] End point indication: no SM1 UV spot on the TLC plate.

[0081] ③Storage: Store at room temperature, sealed.

[0082] Test Example 1 Small Test

[0083] Compared with the process of Example 4, the difference is that the refining step lacks a decolorization step.

[0084] The batch size is 50-100 g. The main process parameters of the preparation method are shown in Table 5.

[0085] Test Example 2 Pilot Production

[0086] The process is exactly the same as that in Example 4, with a batch production of 3 kg. The main process parameters of the preparation method are shown in Table 5.

[0087] Test Example 3 Large-scale production

[0088] The process is exactly the same as that in Example 4, with a batch size of 4.0 kg. The main process parameters of the preparation method are shown in Table 5.

[0089] Table 5. Summary of main parameters of production process of Experimental Examples 1-3

[0090]

[0091]

[0092] The appearance of the crude famotidine obtained in Test Example 1 is darker than that in Test Examples 2-3. The detection results of related substances in Test Examples 2-3 are shown in Table 6.

[0093] Table 6. Summary of quality inspection of famotidine finished product

[0094]

[0095]

[0096] The samples of Test Example 2-3 were tested according to the quality standard of Intermediate I. The results are shown in Table 7.

[0097] Table 7. Test results of related substances of intermediate Ⅰ

[0098]

[0099]

[0100] Note: Guanylthiourea, impurity O and impurity Q have not been included in the quality standards. Based on the results of the supplementary verification, relative retention time positioning is used to list the test results of Guanylthiourea, impurity O and impurity Q in the verification batches 221201, 221202 and 221203. There were slight differences in the elution gradients during the inspection of the pilot batches 220701, 220702 and 220703, and the results were not statistically analyzed. The impurities of related substance 2 are the test results after the study and have not been finally included in the quality standards. This item is not included in the inspection report.

[0101] The above 6 batches of samples of Test Example 2-3 were tested according to the quality standard of Intermediate II. The results are shown in Table 8 below.

[0102] Table 8. Test results of related substances of intermediate II

[0103]

[0104]

[0105] Note: The quality standard of intermediate II in the pilot stage does not include thiourea inspection items. The thiourea inspection results of batches 220701, 220702 and 220703 are the inspection results after method validation.

[0106] Six batches of samples were tested according to the crude product quality standard, and the results are shown in the following table:

[0107] Table 9. Test results of crude famotidine

[0108]

[0109]

[0110] Note: Batches 220701, 220702 and 220703 were tested according to the draft quality standards for the pilot stage. The inspection items of impurities E, H, I, J and K under the relevant substances, urea and 3-chloropropionitrile were not included in the quality standards. The test results of impurities E, H, I, J and K under the relevant substances are listed here according to the relative retention time of impurities. The test results of urea and 3-chloropropionitrile are all the results of sampling after method validation; Batches 221201, 221202 and 221203 were tested according to the quality standards for the validation stage. The inspection items of impurities I, J and K under the relevant substances, urea and 3-chloropropionitrile were not included in the quality standards. The test results of impurities I, J and K under the relevant substances are listed here according to the relative retention time of impurities. The test results of urea and 3-chloropropionitrile are all the results of sampling after method validation.

[0111] Test Example 4 Stability Test

[0112] See Tables 10-11. According to the "Guidelines for Stability Testing of APIs and Pharmaceutical Preparations" (9001, General Rules of Part IV of the 2020 Edition of the Chinese Pharmacopoeia), "Technical Guidelines for Stability Studies of Chemical Drugs (APIs and Preparations) (Revised)" and other relevant guidelines, and referring to the relevant provisions of the famotidine quality standard, the properties, melting point, crystal form, clarity and color of acidic solutions, related substances, loss on drying, microbial limits, bacterial endotoxins, content determination and other items of the three batches of products produced in Test Example 2 were inspected for stability.

[0113] Table 10. Stability test samples and test types

[0114]

[0115]

[0116] Table 11. Results of conventional stability studies

[0117]

[0118]

[0119] Test results: According to the quality standard of famotidine, accelerated (40℃±2℃ / 75%±5%RH) and long-term (30℃±2℃ / 65%±5%RH) stability tests were carried out on 3 batches of pilot batch samples of Test Example 2 (Batch Numbers: 220701, 220702, and 220703). After 6 months of accelerated and 6 months of long-term stability tests, the test results of each item met the requirements of the quality standard.

[0120] Comparative Example 1

[0121] The refining process of famotidine raw material disclosed in ZL200910097581.4 is used as comparative example 1. In comparative example 1, due to the high impurity content of crude famotidine, the impurity content of the refined product after refining is 0.1-0.5%, which cannot be reduced to less than 0.1%. The total impurity content of experimental example 3 is 0.04%, which is significantly less than 0.1%.

[0122] Comparative Example 2

[0123] The famotidine synthesis process disclosed in the literature is comparative example 2, literature: Yu Yonghua. Improvement of famotidine synthesis process [J]. Chin. JMAP, 2001 (8): 7.

[0124] The yield of the refined product in Comparative Example 2 was only 60%. The yield of Experimental Example 2 was over 99.1%.

[0125] Although the present invention has been described in detail above by general description, specific implementation methods and experiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A method for preparing famotidine with improved process, characterized in that: The method comprises a refining step of a crude famotidine product, wherein the refining step of the crude famotidine product specifically comprises: S1 a decolorization step of dissolving the crude famotidine product in N,N-dimethylformamide, adding activated carbon, controlling the temperature to 10-30° C., stirring to decolorize for 1 hour, and then filtering; S2 Crystallization step: Add purified water to the filtrate obtained in the decolorization step, control the temperature at 10-30°C, stir and crystallize for 1-3 hours, and then filter; S3 alcohol washing step: dissolving the filter cake obtained in the crystallization step in methanol, stirring and beating at a temperature of 10-30°C for 1 hour, and then filtering; In step S4 of drying, the filter cake obtained in the step of washing with alcohol is dried under reduced pressure to obtain a refined famotidine product.

2. The method for preparing famotidine with improved process according to claim 1, characterized in that: The method also includes a synthesis step of a crude famotidine product, which comprises subjecting (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride and N-sulfuric acid amino-chloropropionamidine hydrochloride to a substitution reaction in 95% ethanol and 1N sodium hydroxide solution to synthesize the crude famotidine product.

3. The method for preparing famotidine with improved process according to claim 2, characterized in that: The synthesis steps of the crude product specifically include: S1: Mix (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride, N-sulfuric acid amino-chloropropionamidine hydrochloride and ethanol. S2 is temperature controlled at 0-10°C and 1N sodium hydroxide solution is slowly added, and the temperature is controlled at 10-30°C and stirred to react for 4-5 hours. S3 adjusts the pH of the reaction solution to 10-11, S4 is cooled to 0-10℃ and stirred for crystallization for 2-3h and then filtered. S5: The filter cake obtained in S4 is washed with ethanol and then filtered. S6: drying the filter cake obtained in S5 under reduced pressure.

4. The method for preparing famotidine with improved process according to claim 2, characterized in that: The method also includes the step of synthesizing (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride, which specifically includes: mixing 2-guanidino-4-chloromethylthiazole hydrochloride, thiourea and 95% ethanol, heating to 80±5° C. and refluxing, stirring for reaction for 4-5 hours, and after the reaction is completed, cooling to 10-30° C. and stirring for crystallization for 1-2 hours, filtering, washing the filter cake with 95% ethanol, and drying under reduced pressure at 70-80° C. for not less than 4 hours to obtain (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride.

5. The method for preparing famotidine with improved process according to claim 4, characterized in that: The method also includes the step of synthesizing 2-guanidino-4-chloromethylthiazole hydrochloride, and the step of synthesizing 2-guanidino-4-chloromethylthiazole hydrochloride specifically includes: uniformly mixing guanylthiourea and 1,3-dichloroacetone in a molar ratio of 1:1.2 in acetone, slowly heating to 50°C-55°C, refluxing, and continuously stirring for 3-4 hours to obtain a crude solution of 2-guanidino-4-chloromethylthiazole hydrochloride.

6. The method for preparing famotidine with improved process according to claim 5, characterized in that: The method also includes cooling the crude solution of 2-guanidino-4-chloromethylthiazole hydrochloride to 10-30°C, stirring and crystallizing for 1-2 hours, filtering, collecting the filter cake, adding the filter cake and 12L of anhydrous ethanol, stirring and slurrying at 0-20°C for 1 hour, filtering, collecting the filter cake, and drying under reduced pressure at 80-90°C for not less than 4 hours to obtain the 2-guanidino-4-chloromethylthiazole hydrochloride.

7. The method for preparing famotidine with improved process according to claim 1-2, characterized in that: The reduced pressure drying step is to dry under reduced pressure at 70-80° C. for not less than 6 hours.

8. The process for preparing famotidine with improved process according to claim 1, characterized in that: In the refining step of the crude famotidine, the feed ratio of the crude famotidine to activated carbon is 1:0.05 (g / g), the feed ratio of the crude famotidine to DMF is 1:3 (g / V), the feed ratio of the crude famotidine to purified water is 1:9 (g / V), and the feed ratio of the crude famotidine to methanol is 1:10 (g / V).

9. The method for preparing famotidine with improved process according to claim 3, characterized in that: In the synthesis step of the crude product, the (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride and N-sulfuric acid amino-chloropropionamidine hydrochloride of S1 are added in a molar ratio of 1:1.1, the feeding ratio of (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride and ethanol is 1:10 (g / V), and the (S)-[(2-guanidino-4-thiazolyl)methyl]isothiourea dihydrochloride of S2 and 1N sodium hydroxide solution are added in a molar ratio of 1:5.5, and 95% ethanol is used in both S1 and S5.

10. The method for preparing famotidine with improved process according to claim 4, characterized in that: 2-guanidino-4-chloromethylthiazole hydrochloride and thiourea were added in a molar ratio of 1:1.1, and the feeding ratio of 2-guanidino-4-chloromethylthiazole hydrochloride and 95% ethanol was 1:5 (g / V).